MA47165A - Inhibiteurs de la poly-adp-ribose polymérase (parp) - Google Patents

Inhibiteurs de la poly-adp-ribose polymérase (parp)

Info

Publication number
MA47165A
MA47165A MA047165A MA47165A MA47165A MA 47165 A MA47165 A MA 47165A MA 047165 A MA047165 A MA 047165A MA 47165 A MA47165 A MA 47165A MA 47165 A MA47165 A MA 47165A
Authority
MA
Morocco
Prior art keywords
parp
adp
poly
inhibitors
ribose polymerase
Prior art date
Application number
MA047165A
Other languages
English (en)
Other versions
MA47165B1 (fr
Inventor
Nan Ji
Arthur Kluge
Bharat Lagu
Taisuke Takahashi
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MA47165A publication Critical patent/MA47165A/fr
Publication of MA47165B1 publication Critical patent/MA47165B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un vecteur ou un diluant pharmaceutiquement acceptable et un composé représenté par la formule structurale suivante : la présente invention concerne également un procédé de traitement d'un sujet atteint d'une maladie qui peut être soulagée par l'inhibition de la poly(adp-ribose)polymérase (parp). Les définitions des variables sont tels que données dans la description.
MA47165A 2016-12-30 2017-12-28 Inhibiteurs de la poly-adp-ribose polymérase (parp) MA47165B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
PCT/US2017/068636 WO2018125961A1 (fr) 2016-12-30 2017-12-28 Inhibiteurs de la poly-adp-ribose polymérase (parp)

Publications (2)

Publication Number Publication Date
MA47165A true MA47165A (fr) 2019-11-06
MA47165B1 MA47165B1 (fr) 2021-06-30

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47165A MA47165B1 (fr) 2016-12-30 2017-12-28 Inhibiteurs de la poly-adp-ribose polymérase (parp)

Country Status (33)

Country Link
US (2) US11034670B2 (fr)
EP (1) EP3562822B1 (fr)
JP (1) JP7141399B2 (fr)
KR (1) KR102606799B1 (fr)
CN (1) CN110167926B (fr)
AR (1) AR110706A1 (fr)
AU (1) AU2017388376B2 (fr)
BR (1) BR112019011676A2 (fr)
CA (1) CA3047137A1 (fr)
CO (1) CO2019007906A2 (fr)
CY (1) CY1124565T1 (fr)
DK (1) DK3562822T3 (fr)
EA (1) EA201991412A1 (fr)
ES (1) ES2875841T3 (fr)
HR (1) HRP20210887T1 (fr)
HU (1) HUE054382T2 (fr)
IL (1) IL267676B (fr)
JO (1) JOP20190115B1 (fr)
LT (1) LT3562822T (fr)
MA (1) MA47165B1 (fr)
MD (1) MD3562822T2 (fr)
MX (1) MX2019007870A (fr)
NZ (1) NZ754385A (fr)
PH (1) PH12019501529A1 (fr)
PL (1) PL3562822T3 (fr)
PT (1) PT3562822T (fr)
RS (1) RS61895B1 (fr)
SA (1) SA519401894B1 (fr)
SI (1) SI3562822T1 (fr)
TW (1) TWI773718B (fr)
UA (1) UA124777C2 (fr)
WO (1) WO2018125961A1 (fr)
ZA (2) ZA201904004B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024467B (zh) * 2015-10-07 2024-08-06 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法
SI3562822T1 (sl) * 2016-12-30 2021-08-31 Mitobridge, Inc. Zaviralci poli-ADP riboza polimeraze (PARP)
US20230027362A1 (en) * 2019-10-30 2023-01-26 Digmbio. Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient
KR20240057402A (ko) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 그람 음성 박테리아 유출 펌프 억제제
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
WO2024061768A1 (fr) 2022-09-19 2024-03-28 Basf Se Composés pesticides azolés
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
EP1272187B1 (fr) 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Ligands du recepteur d3 de la dopamine destines au traitement de la dependance
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
WO2005082887A1 (fr) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. Dérivé de pyrimidine
EP1760071A4 (fr) 2004-06-23 2008-03-05 Ono Pharmaceutical Co Composé ayant une activité de liaison aux récepteurs s1p et utilisation de celui-ci
BRPI0512790A (pt) * 2004-06-30 2008-04-08 Janssen Pharmaceutica Nv derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CN101263125A (zh) 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
EP2520567A3 (fr) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Dérivés d'hétérocycle contenant de l'azote substitués avec un groupe cyclique
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2637669A4 (fr) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Composés hétérocycliques et utilisations de ceux-ci
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
WO2014036022A1 (fr) * 2012-08-29 2014-03-06 Amgen Inc. Composés quinazolinones et leurs dérivés
US9901577B2 (en) 2013-07-31 2018-02-27 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
US9809598B2 (en) 2014-05-07 2017-11-07 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2018026371A1 (fr) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc
SI3562822T1 (sl) * 2016-12-30 2021-08-31 Mitobridge, Inc. Zaviralci poli-ADP riboza polimeraze (PARP)

Also Published As

Publication number Publication date
LT3562822T (lt) 2021-06-10
AU2017388376B2 (en) 2022-01-06
US11034670B2 (en) 2021-06-15
RS61895B1 (sr) 2021-06-30
SA519401894B1 (ar) 2023-02-19
PH12019501529A1 (en) 2020-09-14
WO2018125961A1 (fr) 2018-07-05
PT3562822T (pt) 2021-06-02
US20220033380A1 (en) 2022-02-03
EP3562822A1 (fr) 2019-11-06
MX2019007870A (es) 2019-08-16
NZ754385A (en) 2024-07-05
CN110167926A (zh) 2019-08-23
IL267676A (en) 2019-08-29
JP2020512298A (ja) 2020-04-23
PL3562822T3 (pl) 2021-09-13
CA3047137A1 (fr) 2018-07-05
MD3562822T2 (ro) 2021-07-31
BR112019011676A2 (pt) 2019-10-15
CY1124565T1 (el) 2022-07-22
EP3562822B1 (fr) 2021-03-10
JP7141399B2 (ja) 2022-09-22
TW201834657A (zh) 2018-10-01
UA124777C2 (uk) 2021-11-17
MA47165B1 (fr) 2021-06-30
HUE054382T2 (hu) 2021-09-28
AU2017388376A1 (en) 2019-07-04
JOP20190115B1 (ar) 2023-09-17
ZA201904004B (en) 2022-12-21
IL267676B (en) 2021-09-30
KR102606799B1 (ko) 2023-11-28
AR110706A1 (es) 2019-04-24
WO2018125961A8 (fr) 2019-05-23
DK3562822T3 (en) 2021-05-03
SI3562822T1 (sl) 2021-08-31
US11993585B2 (en) 2024-05-28
KR20190098760A (ko) 2019-08-22
JOP20190115A1 (ar) 2019-05-20
ES2875841T3 (es) 2021-11-11
CN110167926B (zh) 2022-09-13
EA201991412A1 (ru) 2019-11-29
TWI773718B (zh) 2022-08-11
HRP20210887T1 (hr) 2021-07-23
CO2019007906A2 (es) 2019-10-21
ZA202003310B (en) 2021-08-25
US20200071299A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MA47165A (fr) Inhibiteurs de la poly-adp-ribose polymérase (parp)
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA41338B1 (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA54386B1 (fr) Modulateurs de trex1
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
PH12021550743A1 (en) Boron containing pde4 inhibitors
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
MA45127B1 (fr) Dérivés de pyrazole comme inhibiteurs de la kallikréine plasmatique